La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Vistry Group a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Vistry Group..

Vistry Group (OTC:BVHMF) Azioni, Catena delle Opzioni

Vistry Group PLC is a construction company that focuses on residential construction. It operates in two segments: Housebuilding, which develops sites across England and provides private and affordable housing; and Partnerships segment, which partners with housing associations and other public sector businesses across England to deliver either the development of private and affordable housing. Some of its Brands are Bovis, Linden, Vistry Partnerships, and Drew Smith. The company has properties at Warwick, Winnersh, Winchester, Rugby, Wokingham, Devon, Cambridge, Bursledon, among others.

Vistry Group PLC

WIIM

Cleveland-Cliffs shares are trading lower following worse-than-expected Q3 financial results.

LSCC

Lattice Semiconductor shares are trading lower following soft Q4 guidance.

Mission Produce shares are trading higher after the company raised its Q4 guidance above estimates.

Barclays analyst Gena Wang maintains BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) with a Equal-Weight and raises the price target from $7 to $8.

News

Price Target

Analyst Ratings

BCRX

Barclays Maintains Equal-Weight on BioCryst Pharma, Raises Price Target to $8

Barclays analyst Ryan Macwilliams maintains 8x8 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGHT#NASDAQ">EGHT</a>) with a Equal-Weight and raises the price target from $2 to $2.5.

EGHT

Barclays Maintains Equal-Weight on 8x8, Raises Price Target to $2.5

SKYT

SkyWater Technologies shares are trading higher after Piper Sandler maintained an Overweight rating on the stock and raised its price target from $9 to $12.

LUMN

Lumen Highlights Use Of Google Cloud For AI Services

Inozyme Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INZY#NASDAQ">INZY</a>) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.44) by 11.36 percent. This is a 34.48 percent decrease over losses of $(0.29) per share from the same period last year.

Earnings

Earnings Beats

INZY

Inozyme Pharma Q3 EPS $(0.39) Beats $(0.44) Estimate

Veru Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERU#NASDAQ">VERU</a>), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced data from a meta-analysis presentation at ObesityWeek, which took place November 5, 2024, in San Antonio, Texas.
Highlights from the presentation: The objective of the meta-analysis was to determine the effects of enobosarm on body composition in older patients that had obesity who were enrolled in 4 previously conducted randomized clinical trials of enobosarm that measured body composition including Phase 2 older males and postmenopausal women, Phase 2 advanced cancer patients with muscle wasting, and two Phase 3 advanced lung cancer patients with cancer wasting.
Meta-analysis was conducted in older (≥60 years old) subjects with obesity (BMI ≥30), treated with enobosarm 3mg per day versus placebo, and who had a Day 84 (n= 60) and Day 147 (n=45) DEXA scans to assess body composition.
Results of DEXA scan assessments of body composition in older subjects with obesity: At Day 84, enobosarm 3mg treatment compared to placebo resulted in an absolute increase in lean mass (0.05 kg enobosarm vs -1.54 kg placebo) and absolute decrease in fat mass (-1.48 kg enobosarm vs placebo -0.35 kg).
At Day 147, enobosarm 3mg treatment compared to placebo resulted an absolute increase in lean mass (-0.79 kg enobosarm vs -1.77 kg placebo) and absolute decrease in fat mass (-2.05 kg enobosarm vs -0.05 kg placebo).
At Day 147, enobosarm 3mg treated subjects compared to placebo had greater total weight loss by DEXA scan (-2.93 kg for enobosarm and -2.11 kg for placebo).
Enobosarm was generally well-tolerated with no increase in gastrointestinal side effects.

Biotech

General

VERU

Veru Announces Meta-analysis Of Body Composition Data From Older Patients With Obesity Which Supports Potential For Enobosarm To Optimize Weight Loss At ObesityWeek

Monness, Crespi, Hardt analyst Gus Gala downgrades Marqeta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MQ#NASDAQ">MQ</a>) from Buy to Neutral.

Downgrades

Monness, Crespi, Hardt Downgrades Marqeta to Neutral

Barclays analyst Andrew Mok maintains Cigna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) with a Overweight and raises the price target from $405 to $420.

Barclays Maintains Overweight on Cigna, Raises Price Target to $420

Marathon Petroleum Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPC#NYSE">MPC</a>) shares are trading higher after its&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41740316/marathon-petroleum-corp-reports-third-quarter-2024-results" rel="noreferrer noopener">third-quarter results</a>.
Total revenues and other income of&nbsp;$35.4 billion&nbsp;topped the consensus of&nbsp;$32.8 billion.
Adjusted EBITDA was&nbsp;$2.49 billion&nbsp;for the quarter, compared with&nbsp;$5.71 billion in prior year quarter. Refining operating costs per barrel were&nbsp;$5.30&nbsp;versus&nbsp;$5.14&nbsp;a year ago.&nbsp;
Read: <a target="_blank" href="https://www.benzinga.com/news/24/11/41725310/marathon-petroleum-q3-earnings-preview-can-strong-sales-volume-offset-rising-costs" rel="noreferrer noopener">Marathon Petroleum Q3 Earnings Preview: Can Strong Sales Volume Offset Rising Costs?</a>
Refining &amp; Marketing refined product sales volume for the quarter was 3,685 mbpd&nbsp;(vs. 3,596 mbpd a year ago); Crude oil capacity utilization was&nbsp;94% (flat year over year).&nbsp;&nbsp;
Refining&nbsp;&amp; Marketing segment adjusted EBITDA declined to&nbsp;$1.053 billion from&nbsp;$4.373 billion a year ago due to lower market crack spreads.
Adjusted EPS for the quarter was&nbsp;$1.87,&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">above the consensus of&nbsp;$0.98</a>.
As of September-end, Marathon Petroleum had&nbsp;$5.1&nbsp;billion&nbsp;of&nbsp;cash, cash equivalents,&nbsp;and&nbsp;short-term investments and&nbsp;$5 billion&nbsp;available&nbsp;on&nbsp;its bank revolving credit facility.
In the&nbsp;third quarter, the company returned around&nbsp;$3.0&nbsp;billion&nbsp;to shareholders, including&nbsp;$2.7&nbsp;billion&nbsp;in share repurchases and&nbsp;$273&nbsp;million&nbsp;in dividends. Through&nbsp;October 31, the company bought back an additional&nbsp;$0.5 billion&nbsp;of shares.
Additionally, the company&#8217;s board approved an incremental&nbsp;$5 billion&nbsp;share repurchase authorization. With the addition of this new authorization, Marathon Petroleum has&nbsp;$8.5 billion&nbsp;available under its share repurchase authorizations.&nbsp;
On&nbsp;October 30, the company increased its quarterly dividend to&nbsp;$0.91&nbsp;per share. The dividend is payable&nbsp;on December 10 to shareholders of record on&nbsp;November 20.&nbsp;&nbsp;&nbsp;
Outlook: Marathon Petroleum expects&nbsp;fourth-quarter Refining operating costs per barrel of&nbsp;$5.50 and&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">Refinery throughputs of 2,880 mbpd</a>.&nbsp;
Marathon Petroleum owns the general partner and majority limited partner interest in&nbsp;MPLX LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPLX#NYSE">MPLX</a>), which reported&nbsp;third-quarter earnings per limited partner unit of&nbsp;$1.01, missing the consensus of&nbsp;$1.07, and revenues&nbsp;of&nbsp;$2.97 billion,&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41740434/mplx-lp-reports-third-quarter-2024-financial-results" rel="noreferrer noopener">missing the consensus of&nbsp;$3.09 billion</a>.&nbsp;MPLX returned&nbsp;$949 million of capital to unitholders in the quarter.
Investors can gain exposure to the stock via&nbsp;iShares U.S. Oil &amp; Gas Exploration &amp; Production ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/IEO#BATS">IEO</a>) and&nbsp;VanEck Oil Refiners ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRAK#NYSE">CRAK</a>).
Price Action: MPC shares are up 2.80% at $149.00 premarket at the last check Tuesday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41295799/3-midstream-stocks-poised-to-benefit-as-geopolitical-tensions-rise" target="_blank" rel="noreferrer noopener">3 Midstream Stocks Poised to Benefit as Geopolitical Tensions Rise</a></li>
</ul>

Equities

Large Cap

Guidance

Dividends

Buybacks

Movers

CRAK

iShares Dow Jones US Oil & Gas Exploration & Production Index Fund

MPLX

Marathon Petroleum Q3 Earnings: Outpaces Expectations, Powers Up Shareholder Rewards & More

LIND

Lindblad Expeditions shares are trading higher after the company reported better-than-expected Q3 financial results.

DLTR

Dollar Tree shares are trading higher after JP Morgan maintained a Neutral rating on the stock an raised its price target from $70 to $82.

HDSN

Hudson Technologies shares are trading lower after the company reported worse-than-expected Q3 revenue results and Canaccord Genuity cut its price target on the stock from $8.75 to $8.

SPPL

Simpple Ltd shares are trading higher after the company announced its plan to regain NASDAQ compliance.

The Board of Directors approved an incremental $5 billion share repurchase authorization. With the addition of this new authorization, the company has $8.5 billion available under its share repurchase authorizations.&nbsp;

Marathon Petroleum Approved Incremental $5B Stock Buyback Authorization

Management

ADIL

Adial Pharmaceuticals Appoints Vinay Shah As Chief Financial Officer, Effective Nov. 16

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.verint.com%2F&amp;esheet=54147052&amp;newsitemid=20241105841152&amp;lan=en-US&amp;anchor=Verint%26%23174%3B&amp;index=1&amp;md5=cd382155b60eff877615bca4ef844957">Verint&#xAE;</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNT#NASDAQ">VRNT</a>), The CX Automation Company&#x2122;, today announced that a leading bank awarded Verint an $11 million contract for its AI-powered Agent Copilot Bot to assist 6,500 agents in their contact center.&#x2A;
The bank's contact center agents speak with customers for approximately 400 million minutes each year. The Verint AI-powered bot is designed to listen to these calls in the background and provide agents with real-time assistance, including coaching and guidance.
The bank conducted a pilot before awarding the contract and, based on the pilot result, the estimated annual savings from deploying the AI-powered bot is in the tens of millions of dollars.

Contracts

VRNT

Leading Bank Awards Verint $11M Contract For AI-Powered Agent Copilot Bot To Assist 6,500 Agents In Their Contact Center

BEAM

Beam Therapeutics shares are trading lower in reaction to a report indicating a patient in the company's CRISPR-based sickle cell treatment trial died.

Bonhoeffer Capital Management Q4 2023 Letter

Mayar Capital Q1 2024 Letter To Partners

Maran Partners Fund Q1 2024 Letter

U.K. Election: 5 stock sectors likely to benefit from the Labour Party's landslide win

Laughing Water Capital Q2 2024 Letter

Maran Partners Fund Q2 2024 Letter

TPB: A Growth Nicotine And Cannabis-Adjacent Co. That Can Be A Share Buyback Machine

Comments

Vistry Group

Vistry Group (BVHMF) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO